Summary Report of Consolidated Financial Results
For the nine Months Period ended December 31, 2009 (Year ending March 31, 2010)
February 10, 2010
Company name: NIPRO CORPORATION
Code No.8086

TSE/OSE–1st section

URL: http://www.nipro.co.jp/

Representative: Minoru Sano, President and Representative Director
Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division
Filling date of quarterly reporting: February 12, 2010

TEL: (06) 6372-2331

Payment date of cash dividends: (Note: Amounts are truncated to one million yen)
1. Financial results for the nine months ended Dec. 31, 2009 (From April 1, 2009 to Dec. 31, 2009)(1) Consolidated Results of Operations( Note: The % displays show increase/decrease ratio against the same period of the previous year.)

9 months ended Dec. 31, 2009
9 months ended Dec. 31, 2008

9 months ended Dec. 31, 2009
9 months ended Dec. 31, 2008

Net Sales

Operating Income

Ordinary Income

Millions of yen%
133,063 (1.1)
134,543-

Millions of yen%
14,76735.4
10,904-

Millions of yen
12,503
6,290

Earnings
per Share

Diluted Earnings
per Share

100.15 Yen
42.08

Net
%
98.8
-

IncomeMillions of yen
6,352
2,670

%
137.9
-

- Yen
-

(2) Consolidated Financial Position

9 months ended Dec. 31, 2009
Year ended March 31, 2009
(Note) Shareholders’ equity

Total Assets

Net Assets

Millions of yen
355,181
330,640

Millions of yen
112,061
96,560Net Assets
per Share

Equity Ratio
%

Yen

31.1
28.7

1,739.20
1,498.47

9 months ended Dec. 31, 2009 110,307 million yen, Year ended March 31, 2009 95,049 million yen

2. Dividends
Dividends per share(Basis date) End of 1st Quarter End of 2nd Quarteryen
Yen
Year ended March 31, 2009----32.00
Year ending March 31, 2010----23.50
Year ending March 31, 2010(Forecast)---------End of 3rd Quarteryen-------------

Year endyen
0.00----25.00

Year Total
yen
32.00
----48.50(Note) Revisions to the forecast of cash dividens in the current quarter: No

3. Forecast of Consolidated Financial Results for the Year ending March 31, 2010 (From April 1, 2009 to March 31, 2010)(Note: The % displays show increase/decrease ratio against the year ended March 31, 2009)
Operating
Ordinary
Net Sales
Net Income
IncomeIncomeMillions%
Millions%
Millions%
Millions%of yenof yenof yenof yenYear ending March 31, 2010
180,000
2.3
17,40017.8
13,000
31.4
6,050
33.5
(Note) Revisions to the forecast of consolidated financial results in the current quarter : No

- 1 -Earnings
Per Share
Yen
95.35

4. Others(1) Changes in significant subsidiaries during the current period(Changes in specified subsidiaries that caused a change in the scope of consolidation): No(2) Adoption of accounting treatments simplified and unique for preparation of quarterly consolidated financial statements: Yes(Note) For more details please see page 5. [Qualitative information, financial reports and others] 4. Other.
(3) Changes in accounting principles, procedures and disclosure for quarterly consolidated financial reports (to be stipulated in significant
matters for preparation of quarterly consolidated financial reports):[1] Changes by a newly issued accounting pronouncement: No[2] Changes other than [1]: No(4) Issued shares (Common stock)[1] Number of issued shares at end of the period

9 months ended Dec. 31, 2009

(including treasury stock)[2] Number of treasury stock at end of the period

63,878,505 shares
9 months ended Dec. 31, 2009
454,447 shares[3] Average number of shares during the period

9 months ended Dec. 31, 2009
63,426,103 sharesYear ended March 31, 2009
63,878,505 sharesYear ended March 31, 2009
447,874 shares
9 months ended Dec. 31,2008
63,451,760 shares*Disclaimer for appropriate use of forecasted financial results, and other special notes
The projection figures shown above are based on information that was available at the time of preparation and, therefore, actual
performance and other factors may differ from these projections due to changes in circumstances and other developments. More information
concerning these forecasts can be found on page 5. [Qualitative information, financial reports and others] 3. Qualitative information
concerning forecast of consolidated financial results.

- 2 -[Qualitative information, financial statements and others]
1.

Qualitative information concerning consolidated financial results
In the first nine months of Fiscal year 2009(For the nine months ended December 31, 2009), the world economy generally
remains stagnant though it is said to be gradually bottoming out as the excessive uncertainties about the financial system has
decreased and there was trends toward recovery in some parts of the world. In Japan’s economy, the business environment remains
severe because of the worsening employment conditions and emergences of the deflationary concerns, in addition to the Dubai
crisis and sharp exchange rate fluctuations, while there was pickup in production and trend toward recovery in exports.
Under such situation, we have promoted to develop advanced medical equipment, expand the pharmaceutical business, increase
productive efficiency and step up the sales force, so as to improve business performance.
Therefore, the consolidated sales in the first nine months of Fiscal year 2009(For the nine months ended December 31, 2009)
decreased 1.1% compared with the same period a year ago to the 133,063 million yen. As for the profit, 2.0% increase of grossprofit and 11.1% decrease of selling, general and administrative expenses in the first nine months of FY2009 compared with same
period a year ago resulted in operating income of 14,767 million yen, an increase of 35.4% compared with same period a year ago.
Ordinary income in the first nine months of FY2009 increased 98.8% to 12,503 million yen compared with same period a year ago,
thanks to the decrease of Non-operating expenses like Foreign exchange losses and Net income in the first nine months of FY2009
increased 137.9% to 6,352 million yen compared with same period a year ago.
The overviews of the results by segment in the first nine months of FY2009 are as follows.
<Medical equipment division>
As for the domestic sales, the market and business conditions became more and more server because health industry
particularly in medical institution are urged to improve business efficiency under the promotion of medical system reform aimed atcontrolling medical expenses.
Under such circumstances, we showed consistent growth of sales and profit in each field of injection and infusion-related
products such as product for the new influenza, safety-use product and enteral nutrition-related product,
medical-equipment-related products like dialysis system, examine-related products like blood collection tube, blood collectionneedle and blood glucose meter, products related to ventricular assist device and products related to artificial heart-lungs, andvascular-related products like guiding catheters and thrombectomy catheters by means of more active sales promotion andimprovement in sales efficiency.
In the international business, on the other hand, though we faced a serious challenge due to the appreciation of the yen against
U.S. dollar, we have expanded our sales bases and strengthened on-site-based sales activities in expanding market in China andaggressively promoted the sales in Brazil and other Latin American countries and Europe market so that the sales shows consistentincrease. By product, the businesses for artificial organ like dialyzer have grown greatly, injection and infusion-related products
has increased strongly as well as diabetic devices and safety-device-related products with strong market demands have grownsteadily. In addition, we have strongly advanced the inventory reduction, cost saving, so that the earnings condition has improved
drastically.
As a result, net sales of this division decreased 3.6% from the same period a year ago to 82,806 million yen.
<Pharmaceutical division>
We advanced the sales of characteristics drugs and medicines, supported by the policies for the popularization of genericproducts under the advancement of aging society and increase of the establishments introducing DPC. As a result, we showedsteady growth in sales of liquid-and-powder double-bag kits, pre-mixed-bag kits, injectable drug such as plastic-ampoules, andoral drug such as orally disintegrating tablets and extended-release tablets, as well as dialysis-related products such as kit productof substitution fluid for hemofiltration and hemodiafiltration.
We also advanced the contract manufacturing business to build up the structure which enables us to stably supply thehigh-quality products as the largest contract manufacturer group of pharmaceutical products in Japan, as we have started thecontract-manufacturing of steroid injectable drug in new plant and won a new business in oral drug from major drug companies.
As a result, net sales of this division increased 6.2% from the same period a year ago to 43,126 million yen.
- 3 -

<Glass & Materials division>
In the filed of glass for pharmaceutical purposes, the domestic demands of glass tubes for ampoule decreased due to thechanges of forms of container, on the other hand, the business of glass tubes and bottles have relatively done well.
In the field of other glass & materials products, the export of glass for thermos bottles mainly to Middle East Market decreased
due to the worldwide economic stagnation and stronger yen. The sales of glass for lighting purposes to automobile-relatedindustries began to show a recovery trend to a certain extent, the sales of products related to backlight for LCD decreased
significantly due to the price down and the production shift to overseas locations. As for the products other than glasses products,
though the sales of daily commodity related products like Sanitary good did well, other sales remained poor due to the stagnant
consumption.
As a result, net sales of this division decreased 13.7% from the same period a year ago to 6,485 million yen.
<Other division>
Net sales of other division, consisting mainly of sales of machine for manufacture of medical equipment and real estate rentals,
increased 21.5% from the same period a year ago to 645 million yen.
2.

Qualitative information on the consolidated financial position(1) Condition of the assets, liabilities and net assets
Total assets at end of this third quarterly period increased 24,540 million yen to 355,181 million yen from the end of theprevious fiscal year. Current assets increased 13,915 million yen to 174,780 million yen and non-current assets increased 10,624
million yen to 180,400 million yen from end of the previous fiscal year. Current assets increased mainly due to the increase of
7,282 million yen in the Notes and accounts receivable-trade and non-current assets increased mainly due to the increase of 12,192
million yen in investment securities.
Total liabilities at end of this third quarterly period increased 9,039 million yen to 243,119 million yen from the end of theprevious fiscal year. Current liabilities increased 10,565 million yen to 125,361 million yen and non-current liabilities decreased
1,525 million yen to 117,758 million yen from end of the previous fiscal year. Current liabilities increased mainly due to theincrease of 14,183 million yen in short-term loans payable and non-current liabilities decreased mainly due to the decrease of
14,000 million yen in convertible bond-type bonds with subscription rights to shares.
Net assets at end of this third quarterly period increased 15,501 million yen to 112,061 million yen from the end of theprevious fiscal year. Shareholders’ equity increased 4,850 million yen to 104,094 million yen and valuation and translation
adjustments increased 10,407 million yen to 6,212 million yen from end of the previous fiscal year. Shareholders’ equity increased
mainly due to the increase of 4,861 million yen in retained earnings, and valuation and translation adjustments increased mainly
due to the increase of 7,866 million yen in Valuation difference on available-for-sale securities.
(2)Condition of the consolidated Cash flows
Cash and cash equivalents (hereinafter referred to as “net cash”) at the end of this third quarterly period increased 4,014
million yen to 49,366 million yen from the end of the previous fiscal year.
(Cash flows from operating activities)
Net cash provided by operating activities amounted to 15,681 million yen. The main accounts of inflow were income before
income taxes and minority interests, 11,824 million yen, depreciation and amortization, 13,401 million yen and the main accountsof outflow were increase in notes and accounts receivable-trade, 9,286 million yen, income taxes paid, 4,091 million yen.

- 4 -(Cash flows from investing activities)
Net cash used in investing activity amounted to 22,427 million yen. The main account of outflow was purchase of noncurrent
assets, 22,947 million yen.
(Cash flows from financing activities)
Net cash provided by financing activities amounted to 11,254 million yen. The main accounts of inflow was increase in net
increase in short-term loans payable, 12,839 million yen, commercial paper, 10,000 million yen, and proceeds from long-termloans payable, 17,777 million yen and the main accounts of outflow were repayment of long-term loans payable, 13,560 million
yen and redemption of bonds 17,120 million yen.
3.

Qualitative information concerning forecast of consolidated financial results
There is little sign of recovery in the world economic future, while the growing economic power of newly developing countries is
expected. In Japan’s economy, there is no good prospect for rapid recovery of business investment and personal consumption as
well, and the business environment is expected to remain more severe for a while.
Under such circumstances, we will strive to improve production efficiency and develop sales structure continuously andaggressively develop new business field so as to improve business performance furthermore.
As for the forecast of consolidated financial results for the fiscal year 2009(April 1, 2009 through March 31, 2010), as thebusiness performance for the FY2009 is continuing to perform as expected, there is no changes in the forecast announced on
November 11, 2009.
Although we announced on February 3, 2010 to process the tender offer and the following merger and acquisition of Home
Diagnostics, Inc., we expect at this moment that it would give minimal affection to the consolidated financial statements for
FY2009.

4.

Other(1) Changes in significant subsidiaries during the current period (Changes in specified subsidiaries that caused a change in thescope of consolidation)
N/A(2) Simplified accounting procedures and accounting procedures specific to quarterly consolidated financial statements[1] Simplified accounting procedures
1) Calculation of estimated impairment for general receivables
As it was accepted that there was no significant change between the actual rate or index of bad debts accrual calculated at theend of the current quarterly consolidated accounting period and at the end of the previous consolidated accounting year, thelater rate or index was utilized for estimation of impairment of general receivables.
2) Measurement for inventory
As for the inventory amount at end of the current quarterly consolidated accounting period, actual stock counting procedure
was omitted and the inventory amount was calculated by the reasonable method based on the actual stock balance at end of thesecond quarter of this consolidated accounting year.
3) Calculation method for depreciation of noncurrent assets
The noncurrent assets depreciated in declining balance method were calculated by prorating the depreciation amount in the
consolidated accounting year.
4) Deferred tax assets and liabilities
As for the judgment of collectability of deferred tax assets, the forecasted financial results and tax planning used in the end of
the previous consolidated accounting year was utilized, as it was accepted that there was no significant change in the situationof accrued temporally differences from the end of the previous consolidated accounting year.
[2] Accounting procedures specific to quarterly consolidated financial statements
N/A(3) Changes in accounting principles, procedures, and disclosure for quarterly consolidated financial statements
N/A

- 5 -

5. Quarterly Consolidated Financial Statements(1) [ Quarterly Consolidated Balance Sheets ](Amount: million yen)

As ofDecember 31, 2009
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery, equipment and vehicles, net
Land
Lease Assets
Accumulated depreciation
Lease Assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease Assets
Other
Total intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Guarantee deposits
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-6-

As of
March 31, 2009

53,27958,22938,432
6,046
9,648
3,118
6,513
(488)
174,780

49,20050,94735,759
6,410
8,944
2,846
7,167
(410)
160,865

107,173(55,578)
51,595
116,423(78,723)
37,69919,752
1,325
(111)
1,213
10,601
24,621(20,194)
4,427
125,289

101,361(52,229)
49,131
107,843(71,319)
36,524
19,45993(11)81
16,84723,394(18,699)
4,694
126,739

638
65
1,608
2,312

851
1,597
2,448

49,062
160
4,132
2,583
(3,142)
52,797
180,400
355,181

36,869
140
4,229
2,561
(3,214)
40,587
169,775
330,640

(Amount: million yen)

As ofDecember 31, 2009
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Lease obligations
Accounts payable-other
Income taxes payable
Provision for bonuses
Provision for directors' bonuses
Provision for loss on business liquidation
Notes payable-facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Convertible bond-type bonds
with subscription rights to shares
Long-term loans payable
Lease obligations
Deferred tax liabilities
Provision for retirement benefits
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Valuation and translation adjustments
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total valuation and translation adjustments
Minority interests
Total net assets
Total liabilities and net assets

-7-

As of
March 31, 2009

29,36562,362
10,000
3,130
299
3,976
3,668
1,391
135
1,954
3,092
5,984
125,361

28,322
48,179
6,140
72
4,437
2,281
1,615
3
1,954
14,452
7,336
114,795

38,05035,160-14,00067,855
1,105
6,277
2,056
600
170
1,644
117,758
243,119

65,012
92
913
1,888
631
170
1,416
119,284
234,080

28,66329,972
46,319(860)
104,094

28,66329,97341,457(849)
99,244

12,864(6,652)
6,212
1,754
112,061
355,181

4,998(9,193)(4,195)
1,511
96,560330,640

(2) [ Quarterly Consolidated Statements of Income ][ First nine months ended Dec. 31, 2009 ](Amount: million yen)
FY2008 first nine months FY2009 first nine months(From April 1, 2008
(From April 1, 2009
to Dec. 31, 2008)
to Dec. 31, 2009)
134,543
133,063
95,90893,642
38,63539,421
27,73024,653
10,904
14,767

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Depreciation
Foreign exchange losses
Equity in losses of affiliates
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
Settlement received
Compensation income
Surrender value of insurance
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Impairment loss
Abnormal manufacturing cost
Loss on valuation of inventories
Corresponding loss to compensation income
Loss on product recovery
Other
Total extraordinary losses
Income before income taxes and minority interests
Income taxes-current
Income taxes-deferred
Total income taxes
Minority interests in income
Net income

-8-

341
721
405
1,468

175
598
534
1,308

1,722
271
3,881
137
70
6,083
6,290

1,694
166
534
1,055
121
3,571
12,503

278
200
161
640

23
193
109
26
352

140
130
362
229
316
1,180
5,750
2,554
332
2,886
193
2,670

53
486
190
159
142
1,031
11,824
5,521
(295)
5,225
246
6,352

(3) [ Quarterly Consolidated Statements of Cash Flows ](Amount: million yen)

Net cash provided by (used in) operating activities
Income before income taxes and minority interests
Depreciation and amortization
Impairment loss
Amortization of goodwill
Equity in (earnings) losses of affiliates
Increase (decrease) in allowance for doubtful accounts
Interest and dividends income
Interest expenses
Foreign exchange losses (gains)
Decrease (increase) in notes and accounts receivable-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Decrease (increase) in other assets
Increase (decrease) in other liabilities
Other loss (gain)
SubtotalInterest and dividends income received
Interest expenses paid
Other proceeds
Other payments
Income taxes paid
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of investment securities
Purchase of noncurrent assets
Proceeds from sales of noncurrent assets
Proceeds from governmental subsideies
for investment in property and equipment
Net Decrease (increase) in short-term loans receivableCollection of loans receivable
Other payments
Other proceeds
Net cash provided by (used in) investment activities-9-

FY2008 first nine months(From April 1, 2008
to Dec. 31, 2008)

FY2009 first nine months(From April 1, 2009
to Dec. 31, 2009)

5,750
13,120
130
261
137
385
(1,063)
1,722
1,140(10,451)(5,712)
7,382
(731)
(179)
(490)
11,403
1,011(1,618)730(247)(3,403)
7,876

11,824
13,401
220
1,055
1
(773)
1,694
32
(9,286)(2,558)
5,060
230
(765)
(76)
20,059882(1,507)763(425)(4,091)
15,681(2,267)2,001(374)(16,171)377(1,679)1,604(8)(22,947)
55

1,838

202

97
48
0
1
(14,447)343
0
2(22,427)

(Amount: million yen)

Net cash provided by (used in) financing activities
Net increase (decrease) in short-term loans payable
Increase (decrease) in commercial paper
Proceeds from long-term loans payable
Repayment of long-term loans payable
Proceeds form issuance of bonds
Redemption of bonds
Proceeds from stock issuance to minority shareholders
Decrease (increase) in treasury stock
Repayments of finance lease obligations
Cash dividends paid
Cash dividends paid for minority shareholders
Other payments
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Increase in cash and cash equivalentsfrom newly consolidated subsidiary
Cash and cash equivalents at end of period- 10 -

FY2008 first nine months(From April 1, 2008
to Dec. 31, 2008)

FY2009 first nine months(From April 1, 2009
to Dec. 31, 2009)

1,877
20,250(10,992)(10,130)
9
(51)
(30)
(2,595)0(1,662)(1,150)(9,384)47,656

12,83910,00017,777(13,560)
2,982(17,120)(11)(152)(1,477)(2)(21)
11,254(494)
4,014
45,352809-

39,08249,366

(4) Notes related to going concern
N/A(5) Segment information[1] Segment information by business category

FY2008 first nine months (From April 1, 2008 to Dec. 31, 2008)
MedicalEquipment
Net sales(1)Sales to third parties(2)Inter-segment sales
and transfers

Pharmaceutical

Glass &
Materials(Amount: million yen)
Other

Total

Eliminations/Corporate

Consolidated

85,874

40,624

7,514

530

134,543-

134,543

-

0

2,529

56

2,586

(2,586)-

Total

85,874

40,624

10,044586

137,130(2,586)

134,543

Operating income(loss)

11,418

3,573

1,370

8

16,371(5,466)

10,904

FY2009 first nine months (From April 1, 2009 to Dec. 31, 2009)
MedicalEquipment
Net sales(1)Sales to third parties(2)Inter-segment sales
and transfers

Pharmaceutical

Glass &
Materials(Amount: million yen)
Other

Total

Eliminations/Corporate

Consolidated

82,806

43,1266,485

645

133,063-

133,063

-

0

3,079

70

3,149

(3,149)-Total

82,806

43,126

9,564

715

136,213(3,149)133,063

Operating income(loss)

14,045

4,037

1,417

70

19,571(4,803)

14,767(Notes) 1. Classification of business categories and main products and commodities in each business category
Business categories are classified based on the proximity in terms of purposes and manners of usage of the
products in the market.
Main products belonging to each business categories are as follows:Business
category

Main products and commodities

MedicalEquipment

Dialyzers, blood tubing sets, injection needles, syringes, and infusion sets, etc.

Pharmaceutical

Half-type and full-type kits, double-bag kits, pre-filled syringes, dialysate solution, andcirculatory drugs, etc.

Glass &
Materials

Glass for pharmaceutical containers, glass for thermos bottles, glass for lighting purposes,
stoppers for plastic containers and rubber stoppers, etc.

Other

Machinery for manufacture of medical equipment and real estate rental income, etc.

- 11 -

[2] Segment information by geographical area

FY2008 first nine months (From April 1, 2008 to Dec. 31, 2008)
Japan

Net sales(1)Sales to third parties(2)Inter-segment sales
and transfers
Total
Operating income(loss)

America

Europe(Amount: million yen)
Asia

Total

103,585

15,879

9,344

5,734

134,543-

134,543

24,051742

110,85835,653(35,653)-

127,636

16,621

9,345

16,593

170,197(35,653)

134,543

16,134

(741)

3

910

16,307(5,402)

10,904

FY2009 first nine months (From April 1, 2009 to Dec. 31, 2009)
Japan

Net sales(1)Sales to third parties(2)Inter-segment sales
and transfers
Total
Operating income(loss)

Eliminations
Consolidated/Corporate

America

Europe(Amount: million yen)
Asia

Total

Eliminations
Consolidated/Corporate

104,723

13,209

9,613

5,517

133,063-

133,063

22,356488

311,43934,287(34,287)-

127,079

13,697

9,616

16,956167,351(34,287)

133,063

18,301

(49)

78

1,652

19,982(5,214)

14,767(Notes)1. Classification of countries or areas is based on geographical proximity.
2. The major countries included in each geographical area are as follows:
America…….. The United States of America and Brazil
Europe……… Belgium
Asia…………. China, Thailand and Singapore- 12 -

[3] Overseas Sales

FY2008 first nine months (From April 1, 2008 to Dec. 31, 2008)
America

1. Overseas sales

Europe25,32614,995(Amount: million yen)
Asia

Total

7,921

134,543

2. Consolidated net sales
3.

Percentage of overseas sales toconsolidated net sales (%)

18.8%

11.2%

5.9%

FY2009 first nine months (From April 1, 2009 to Dec. 31, 2009)
America

1. Overseas sales

Europe21,121

15,226Percentage of overseas sales toconsolidated net sales (%)

35.9%(Amount: million yen)
Asia

Total

7,744

44,092133,063

2. Consolidated net sales
3.

48,244

15.9%

11.4%

5.8%

33.1%

(Notes) 1. Overseas sales represent those of the Company and the consolidated subsidiaries to countries and are
as outside of Japan
2. Classification of countries or areas is based on geographical proximity.
3. The major countries included in each geographical area are as follows:
America……… The United States of America, Canada and Brazil
Europe………. Belgium, Denmark and Germany
Asia………….. China, India, Indonesia, Taiwan and Thailand(6) Notes to Statements of Shareholders’ Equity, if having significant variation.
N/A- 13 -